Phosphate Derivative Synthesis for Diastereoisomeric Purity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for preparing ProTides such as NUC-3373, NUC-7738, and NUC-9701 are not scalable, economic, or efficient, particularly in achieving diastereoisomerically pure forms.
Innovation Solution
A process involving the reaction of specific compounds with a base to achieve diastereoisomerically pure forms of NUC-3373, NUC-7738, and NUC-9701, utilizing stepwise removal of protecting groups to obtain the ProTides in substantially pure form.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional methods are used to prepare ProTides, then the synthesis can be completed, but the manufacturing precision and productivity are insufficient due to inability to achieve diastereoisomerically pure forms
Solution Approach 1:
The patent applies preliminary action by performing a base treatment step before the final coupling reaction. This preliminary deprotection/enrichment step converts a mixture of diastereoisomers into substantially diastereoisomerically pure compound, which then proceeds to the final ProTide product with high purity. This resolves the contradiction by preparing the material in advance to achieve both high purity and efficient final synthesis.
Solution Approach 2:
The patent utilizes parameter changes by altering the pH conditions through base treatment. The base (such as sodium hydroxide or potassium hydroxide) changes the chemical environment to induce epimerization and enrichment of the desired diastereoisomer. This parameter change enables selective transformation that achieves diastereoisomeric purity without requiring complex separation processes, thereby maintaining productivity.
2Manufacturing precision
If diastereoisomerically pure ProTides are produced through conventional methods, then purity is achieved, but the process is not scalable or economic
Solution Approach 1:
The patent applies the taking out principle by removing protecting groups selectively through base treatment. This extraction of the protecting group reveals the desired diastereoisomer in pure form, eliminating the need for complex purification and separation processes. The method is simple, scalable, and economically viable while achieving diastereoisomeric purity.
Solution Approach 2:
The patent uses parameter changes (pH adjustment via base treatment) to achieve diastereoisomeric enrichment in a straightforward, scalable manner. This chemical parameter change is easily implementable on large scale and does not require sophisticated equipment or complex procedures, making the process both economical and scalable while maintaining high purity.
3Reliability
If protecting groups are removed to obtain pure ProTides, then the therapeutic effectiveness is maintained, but additional process steps are required
Solution Approach 1:
The patent applies preliminary action by performing the deprotection step as part of the synthesis sequence before final isolation. The base treatment removes protecting groups and enriches the desired diastereoisomer in one integrated operation, ensuring therapeutic effectiveness is maintained while avoiding the need for separate, complex purification steps afterward.
Solution Approach 2:
The base treatment step serves multiple functions simultaneously: it removes protecting groups, enriches the desired diastereoisomer, and prepares the compound for final coupling. This multi-functionality reduces the overall number of process steps required while ensuring the therapeutic effectiveness of the final ProTide product.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process allows for the efficient production of diastereoisomerically pure ProTides, meeting regulatory criteria for trace impurities and enabling large-scale manufacture while maintaining therapeutic effectiveness.
Implementation Method 1
reacting a compound of Formula IIa; wherein R1 represents an electron withdrawing group and a is an integer from 1 to 5, with a compound of Formula IIIa in presence of a base (B1) to provide a compound of Formula IVa in substantially diastereomerically pure form
Data Source
AI summary
The present invention is a process for the preparation of certain 5′-phosphoramidate nucleotide diastereoisomers. The phosphoramidates include those useful in the treatment of cancer such as NUC-3373 (5-fluoro-2′-deoxyuridine-5′-O-[1-naphthyl(benzyloxy-L-alaninyl)]phosphate].